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stra. The author summarizes the con-
cepts, and discusses the problems
relating to high-throughput protein
identification and data analysis. Finally,
in the last chapter, D. C. Liebler reviews
bioinformatic tools for proteomics,
notably for peptide sequence identifi-
cation with MS data, the approaches for
protein identification analysis of unin-
terpreted data, the role of software for
de novo sequence interpretation from
MS/MS data and presents other soft-
ware packages used by the proteomic
community.
In summary, the book is well struc-
tured and constructed, and globally,
well written. The figures are of excel-
lent quality. The book is highly recom-
mended for all people, expert or not,
who need simple, clear answers to
common problems encountered in
proteomics.
Professor Jean-Daniel Tissot
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This fresh edition of an established
publication from the International
Union Against Cancer (UICC) is both
sobering and useful for proteomics. The
book consists of six substantial chapters
about principles of prognosis, and 39
brief chapters about as many different
types of cancers, using a standardized
format. The summary table for each
tumor type provides a matrix of the
tumor-related, host-related, and envir-
onmentally-related essential, additional,
and promising prognostic factors that
should be obtained for the patient and
research records.
From the time of Hippocrates,
prognosis was the physician’s primary
function, assisting patients to antici-
pate the likely outcomes of their dis-
ease. Since the emergence of modern
diagnosis and therapies, prognosis has
been neglected by physicians, say the
various authors, despite its overriding
importance for patients. “Diagnosis
means generalizing, transcending the
particular; prognosis. . .means indivi-
dualizing” (cited, p. 5). Prognosis, in
fact, is a key element of the vision many
of us hold of predictive, personalized,
and preventive (P3) healthcare.
What is sobering is how little from
proteomics, or other molecular meth-
ods, has permeated oncology practice
and clinical guidelines to date. “Prote-
omics” does not appear in the glossary,
although “biomarker”, “DNA arrays”,
and “molecular prognostic factor” do.
“Protein-based prognostic factors” and
”proteomics” make the index just
twice. First, there is one page (p. 83–
84) of general description, with 13
citations, a conclusion that no clinical
integration of proteomic technology
into prognostic classification systems
has taken place (yet), but a projection
that molecular characteristics will be
incorporated into future prognostic
systems. The second is a mere men-
tion that “genomic- and proteomic-
based studies have led to the identifi-
cation of a large number of candidate
biomarkers in prostate cancer”
(p. 248). The only specific biomarkers
highlighted are microvessel density
and Ki-67, to be used in conjunction
with TNM, prostate-specific antigen
(PSA) level, and Gleason score. Like-
wise, it is sobering to read that a liter-
ature review of neuroblastoma noted
130 different markers investigated in
211 studies, with a median of one
publication per marker. Cancers for
which there is useful text about mo-
lecular prognostic factors are esopha-
geal, colorectal, hepatocellular, pan-
creatic, lung (rather weak), breast
(most extensive), endometrial, pros-
tate, and non-Hodgkin lymphoma.
Some authors distinguish prognostic
(overall outcome) from predictive (re-
sponse to therapy) applications.
The book will be useful to
researchers designing studies using
proteomics and panels of marker can-
didates to characterize heterogeneity of
outcomes among patients with similar
clinical, radiological, and histopatholo-
gical features. Many papers already
report molecular subgrouping of
patients with big differences in
Kaplan-Meier survival curves. Chapter
3 provides a good primer for design of
study protocols, including exploratory
(phase II) and confirmatory (phase III)
studies and the risks of misleading
results from failing to formulate
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hypotheses, inadequate patient and
event numbers, inappropriate multiple
significance testing, overfitting regres-
sion models, and failing to verify with
independent datasets. Guidelines for
Reporting Tumor Marker Prognostic
Studies (REMARK) are included. The
clinical annotations provided to us
must have detailed, credible TNM sta-
ging (T = tumor size or extent; N =
tumor-bearing lymph nodes; M =
metastatic lesions).
Protein biomarkers will be used to
predict survival, disease-free interval,
or quality of life in individuals already
diagnosed (monitoring) and to screen
undiagnosed individuals in the general
population or subpopulations con-
sidered to be at-risk due to known
exposures or precursor lesions. We
should check that our clinical collea-
gues used the evidence-based “essen-
tial prognostic factors” in characteriz-
ing the patients and choosing the
therapies. If the patients are not well-
matched, including co-morbidities,
differences correlated with molecular
phenotypes may be misleading or add
little value in a multivariate analysis.
Conversely, adequate documentation
will facilitate comparison of results,
and meta-analyses, from different
studies. The screening mode requires
very high specificity and good sensitiv-
ity, in order to generate a useful posi-
tive predictive value; otherwise, most
positive tests will be “false-positives”.
In contrast, the prognostic mode is
focused on already-diagnosed patients,
so the challenge lies in heterogeneity,
not low prevalence. Finally, we should
heed the distinction (p. 19) between
predetermined prognosis and prog-
nosis dependent upon later events. For
example, an overall 50% long-term
survival rate with a chemotherapy
regimen might be due to differences
already existing at the time of clinical
evaluation, such that only 50% will
respond at any dose, or might be due
to therapy at the TCD50 concentration,
so that patients might do a lot better at
a higher dose, if tolerated.
Properly conducted clinical prote-
omics studies should add considerable
value to both diagnosis and prognosis
of cancers. Validated results may be
feasible earlier for prognostic uses.
Gilbert S. Omenn
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The human genome has been
sequenced and protein-coding genes
have been counted to be around 31,000
genes by the Human Genome Project.
Those genes are thought to produce
more than a million different proteins
through both different mRNA splicing
and various post-translational mod-
ifications, and protein expression with
a 106 2108 dynamic range varies dyna-
mically along the lifetime of a cell. We
are now able to answer the question as
to what genes really do, how molecular
machineries are created and/or
destroyed, and how they interplay as
members of a biological system to
make up life. Many cellular processes
are performed and regulated not by in-
dividual proteins but by proteins acting
in large protein assemblies or macro-
molecular complexes.
This 944-page book collectively cov-
ers the current understanding of
chemical biology of oxidative stress and
physiology, proteomic technologies,
redox proteomics in normal cellular
physiology and pharmacology, and pro-
teomic applications to disease states.
Numerous disease states and normal
aging involve oxidative modification of
proteins which would result in cellular
dysfunction. Changes in the reductive
or oxidative capacity of the cell lead to
post-translational modification of pro-
teins by reactive oxygen species (ROS) /
reactive nitrogen species (RNS) via
“redox cell signaling”. Redox Proteom-
ics focuses considerably on protein
modifications and identifies oxidatively
modified proteins in both a qualitative
and quantitative manner in order to
attain molecular mechanisms of cel-
lular dysfunction and to investigate the
effects of disease, metabolism, phar-
macological agents, aging and so on.
The fundamental background of
chemical protein modifications of bio-
logical systems under oxidative stress
are comprehensively and educationally
introduced in the early chapters. Vari-
eties of methodological developments
revised for proteomic research are
referred to, including multi-
dimensional protein identification
technology (MudPIT) and isotope-
coded affinity tag (ICAT), to identify
and quantify oxidant-sensitive post-
translational modifications. Critical
reviews on analytical methods using
mass spectrometry and other meth-
odologies are also beneficial. When an
excess of reactive species or endoge-
nous reduction of antioxidant defense
system occurs, proteins, lipids, DNA
and other macromolecular complexes
are targeted to be oxidative modifica-
tions. An accumulation of altered
forms of nucleic acids, lipids, and pro-
teins damages cellular and tissue func-
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